Originally published as JCO Early Release 10.1200/JCO.2005.03.045 on February 22 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D'Addario, G. Articles by Shepherd, F. A. Search for Related Content PubMed PubMed Citation Articles by D'Addario, G. Articles by Shepherd, F. A. Related Articles Related Editorial Social Bookmarking                            What's this?

Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature

From the Kantonsspital St Gallen, Departement Innere Medizin, Fachbereich Onkologie-Haematologie, St Gallen, Switzerland; Princess Margaret Hospital, Toronto, Ontario, Canada

Address reprint requests to Giannicola D'Addario, MD, Kantonsspital St Gallen, Departement Innere Medizin, Fachbereich Onkologie-Haematologie, Rorschacherstrasse 95, 9007 St Gallen, Switzerland; e-mail: giannicola.daddario{at}kssg.ch

PURPOSE: This meta-analysis was performed to compare the activity, efficacy and toxicity of platinum-based versus non-platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.

METHODS: Randomized phase II and III clinical trials comparing first-line palliative platinum-based chemotherapy with the same regimen without platinum or with platinum replaced by a nonplatinum agent were identified by electronic searches of Medline, Embase, and Cancerlit, and hand searches of relevant abstract books and reference lists. Response rates, 1-year survival, and toxicity were analyzed. Subgroups of trials using third-generation agents were compared.

RESULTS: Thirty-seven assessable trials were identified including 7,633 patients. A 62% increase in the odds ratio (OR) for response was attributable to platinum-based therapy (OR, 1.62; 95% CI, 1.46 to 1.8; P < .0001). The 1-year survival rate was increased by 5% with platinum-based regimens (34% v 29%; OR, 1.21; 95% CI, 1.09 to 1.35; P = .0003). No statistically significant increase in 1-year survival was found when platinum therapies were compared to third-generation-based combination regimens (OR, 1.11; 95% CI, 0.96 to 1.28; P = .17). The toxicity of platinum-based regimens was significantly higher for hematologic toxicity, nephrotoxicity, and nausea and vomiting, but not for neurotoxicity, febrile neutropenia rate, or toxic death rate.

CONCLUSION: Response is significantly higher with platinum-containing regimens. One-year survival was not significantly prolonged when platinum-based therapies were compared with third-generation-based combination regimens. Toxicity is generally higher for platinum-based regimens.

Published in part in abstract form and orally presented at the 10th World Conference on Lung Cancer, Vancouver, Canada, August 10-14, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Platinums in Lung Cancer: Sufficient or Necessary?
  Paul A. Bunn, Jr
  JCO 2005 23: 2882-2883 [Full Text]

This article has been cited by other articles:

				J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer Ann. Onc., October 15, 2009; (2009) mdp352v1. [Abstract] [Full Text] [PDF]

				Y. W. MOON, J. H. SOHN, Y. T. KIM, H. CHANG, J. H. JEONG, Y. J. LEE, J. CHANG, S. K. KIM, M. JUNG, S. HONG, et al. Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided versus Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer Anticancer Res, October 1, 2009; 29(10): 4243 - 4249. [Abstract] [Full Text] [PDF]

				F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach Oncologist, May 1, 2009; 14(5): 497 - 510. [Abstract] [Full Text] [PDF]

				J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]

				A. M. Hernandez, D. Toledo, D. Martinez, T. Grinan, V. Brito, A. Macias, S. Alfonso, T. Rondon, E. Suarez, A. M. Vazquez, et al. Characterization of the Antibody Response against NeuGcGM3 Ganglioside Elicited in Non-Small Cell Lung Cancer Patients Immunized with an Anti-Idiotype Antibody J. Immunol., November 1, 2008; 181(9): 6625 - 6634. [Abstract] [Full Text] [PDF]

				M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer Ann. Pharmacother., November 1, 2008; 42(11): 1640 - 1652. [Abstract] [Full Text] [PDF]

				S-G. Wu, C-H. Gow, C-J. Yu, Y-L. Chang, C-H. Yang, Y-C. Hsu, J-Y. Shih, Y-C. Lee, and P-C. Yang Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma Eur. Respir. J., October 1, 2008; 32(4): 924 - 930. [Abstract] [Full Text] [PDF]

				I. Okamoto, T. Nishimura, M. Miyazaki, H. Yoshioka, A. Kubo, K. Takeda, N. Ebi, S. Sugawara, N. Katakami, M. Fukuoka, et al. Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 Clin. Cancer Res., August 15, 2008; 14(16): 5250 - 5254. [Abstract] [Full Text] [PDF]

				J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, and A. A. Adjei Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship Mayo Clin. Proc., May 1, 2008; 83(5): 584 - 594. [Abstract] [Full Text] [PDF]

				P. A. Janne, G. R. Simon, C. J. Langer, R. N. Taub, A. Dowlati, P. Fidias, M. Monberg, C. Obasaju, and H. Kindler Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naive Malignant Pleural Mesothelioma J. Clin. Oncol., March 20, 2008; 26(9): 1465 - 1471. [Abstract] [Full Text] [PDF]

				P. A. Kosmidis, H. P. Kalofonos, C. Christodoulou, K. Syrigos, T. Makatsoris, D. Skarlos, C. Bakogiannis, C. Nicolaides, D. Bafaloukos, A. Bamias, et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group Ann. Onc., January 1, 2008; 19(1): 115 - 122. [Abstract] [Full Text] [PDF]

				S. Ramalingam and C. Belani Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Oncologist, January 1, 2008; 13(suppl_1): 5 - 13. [Abstract] [Full Text] [PDF]

				J. O. Park, S.-W. Kim, J. S. Ahn, C. Suh, J. S. Lee, J. S. Jang, E. K. Cho, S. H. Yang, J.-H. Choi, D. S. Heo, et al. Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non Small-Cell Lung Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5233 - 5239. [Abstract] [Full Text] [PDF]

				C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT J. Nucl. Med., May 1, 2007; 48(5): 744 - 751. [Abstract] [Full Text] [PDF]

				P Comella, G Filippelli, G De Cataldis, B Massidda, G Frasci, L Maiorino, C Putzu, S Mancarella, S Palmeri, R Cioffi, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101) Ann. Onc., February 1, 2007; 18(2): 324 - 330. [Abstract] [Full Text] [PDF]

				G. Giaccone, M. Gallegos Ruiz, T. Le Chevalier, N. Thatcher, E. Smit, J. A. Rodriguez, P. Janne, D. Oulid-Aissa, and J.-C. Soria Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study. Clin. Cancer Res., October 15, 2006; 12(20): 6049 - 6055. [Abstract] [Full Text] [PDF]

				J. R. Molina, A. A. Adjei, and J. R. Jett Advances in Chemotherapy of Non-small Cell Lung Cancer. Chest, October 1, 2006; 130(4): 1211 - 1219. [Abstract] [Full Text] [PDF]

				F. Ohyanagi, F. Taguchi, T. Horai, K. Kasahara, Y. Takeda, K. Shibata, H. Shirosaki, and M. Nishio Phase II Study of Combination Chemotherapy with Gemcitabine and Irinotecan in Patients with Advanced Non-Small-Cell Lung Cancer Previously Treated with Platinum-Containing Chemotherapy Regimens Jpn. J. Clin. Oncol., September 1, 2006; 36(9): 547 - 551. [Abstract] [Full Text] [PDF]

				A. Bottomley, R. Gaafa, C. Manegold, S. Burgers, C. Coens, C. Legrand, M. Vincent, G. Giaccone, and J. Van Meerbeeck Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study J. Clin. Oncol., March 20, 2006; 24(9): 1435 - 1442. [Abstract] [Full Text] [PDF]

				M. McCulloch, C. See, X.-j. Shu, M. Broffman, A. Kramer, W.-y. Fan, J. Gao, W. Lieb, K. Shieh, and J. M. Colford Jr Astragalus-Based Chinese Herbs and Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Trials J. Clin. Oncol., January 20, 2006; 24(3): 419 - 430. [Abstract] [Full Text] [PDF]

				H. Wakelee and C. P. Belani Optimizing First-Line Treatment Options for Patients with Advanced NSCLC Oncologist, October 1, 2005; 10(suppl_3): 1 - 10. [Abstract] [Full Text] [PDF]

				M. Tiseo, L. Boni, and A. Ardizzoni Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Does Cisplatin Versus Carboplatin Make a Difference? J. Clin. Oncol., September 1, 2005; 23(25): 6276 - 6277. [Full Text] [PDF]

				P. A. Bunn Jr Platinums in Lung Cancer: Sufficient or Necessary? J. Clin. Oncol., May 1, 2005; 23(13): 2882 - 2883. [Full Text] [PDF]